CAJ | 학술논문

目的:研究肿瘤干细胞标志物CD133和肿瘤血管内皮细胞标志物CD105在肺癌组织中的表达及其临床意义.方法:用免疫组织化学链霉亲和素-生物素-过氧化物酶复合物(streptavidin-biotin-peroxidase complex,SABC)法检测65例肺癌组织和30例癌旁组织中CD133与CD105的表达情况,分析二者与肿瘤大小、组织学类型、组织分化程度、TNM分期、淋巴结转移和预后的关系.结果:肺癌组织CD133和CD105的阳性表达率高于癌旁组织,分别为69.2% vs 26.7%和67.7% vs 10.0%,差异有统计学意义(均P＜0.05).有淋巴结转移组的CD133和CD105阳性表达率高于无淋巴结转移组,分别为82.5% vs 48.0%和80.0% vs 48.0%,差异有统计学意义(均P＜0.05).CD133和CD105的表达与淋巴结转移正相关,Pearson列联系数r分别为0.35和0.32(均P＜0.05).CD133和CD105的表达与肿瘤大小、组织学类型、组织分化程度以及TNM分期无相关性(均P＞0.05).CD133与CD105的表达之间呈正相关,Pearson列联系数r=0.37(P＜0.05).CD133和CD105表达阳性组的术后中位生存期低于阴性组,分别是37个月vs 66个月和35个月vs 70个月,差异有统计学意义(均P＜0.05). 结论:CD133和CD105的表达与肺癌患者的淋巴结转移和预后密切相关,其高表达提示预后不良.
목적:연구종류간세포표지물CD133화종류혈관내피세포표지물CD105재폐암조직중적표체급기림상의의.방법:용면역조직화학련매친화소-생물소-과양화물매복합물(streptavidin-biotin-peroxidase complex,SABC)법검측65례폐암조직화30례암방조직중CD133여CD105적표체정황,분석이자여종류대소、조직학류형、조직분화정도、TNM분기、림파결전이화예후적관계.결과:폐암조직CD133화CD105적양성표체솔고우암방조직,분별위69.2% vs 26.7%화67.7% vs 10.0%,차이유통계학의의(균P＜0.05).유림파결전이조적CD133화CD105양성표체솔고우무림파결전이조,분별위82.5% vs 48.0%화80.0% vs 48.0%,차이유통계학의의(균P＜0.05).CD133화CD105적표체여림파결전이정상관,Pearson렬련계수r분별위0.35화0.32(균P＜0.05).CD133화CD105적표체여종류대소、조직학류형、조직분화정도이급TNM분기무상관성(균P＞0.05).CD133여CD105적표체지간정정상관,Pearson렬련계수r=0.37(P＜0.05).CD133화CD105표체양성조적술후중위생존기저우음성조,분별시37개월vs 66개월화35개월vs 70개월,차이유통계학의의(균P＜0.05). 결론:CD133화CD105적표체여폐암환자적림파결전이화예후밀절상관,기고표체제시예후불량.
Objective:To investigate the expressions of tumor stem cell marker CD133 and tumor vascular endothelial cell marker CD105 in lung cancer tissue and their clinical significance.Methods:Streptavidin-biotin-peroxidase complex (SABC)-immunohistochemical staining was used to detect the expression of CD133 and CD105 in 65 cases of lung cancer tissue and 30 specimens of adjacent non-cancerous tissue. The relationship between the expression of CD133/CD105 and tumor size, histological types, differentiation, TNM stage, lymphoid metastasis, and prognosis were analyzed. Results:The positive expression rates of CD133 and CD105 in lung cancer tissues were significantly higher than those in adjacent non cancerous tissues, respectively (69.2% vs 26.7% and 67.7% vs 10.0%, both P<0.05). The positive expression rates of CD133 and CD105 in the group with lymphoid metastasis were higher than those with non lymphoid metastasis, respectively (82.5% vs 48.0% and 80.0% vs 48.0%, both P<0.05). The expressions of CD133 and CD105 were positively correlated with lymphoid metastasis with Pearson coefficient r of 0.35 and 0.32, respectively (P<0.05). No significant correlation was found between the expression of CD133/CD105 and tumor size, histological types, differentiation degree as well as TNM stage(P>0.05). The expression of CD133 was positively correlated with the expression of CD105 in lung cancer tissue with Pearson coefficient r of 0.37 (P<0.05). Postoperative median survival periods of CD133 and CD105-positive group were significantly shorter than the CD133 and CD105-negative groups (37 months vs 66 months,35 months vs 70 months, respectively, both P<0.05). Conclusion:The expression of CD133 and CD105 was associated with lymphoid metastasis and prognosis in patients with lung cancer.Their overexpression implies poor prognosis of lung cancer patients.